Program
codrituzumab
Also written as “GC33” and “GC33(RO5137382)”.
Its studies are mostly in Carcinoma, Hepatocellular, led by Hoffmann-La Roche.
Furthest: phase 2, since Jan 6, 20123 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 30 open or running | phase 2since Jan 6, 2012 | Sep 1, 2008 | none ahead |
- Named in Hoffmann-La Roche’s own pipeline as
CHU codrituzumab
, phase 1, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 1, 2008First study: phase 1 study in Advanced or Metastatic HCCFirst studyNCT00746317 · 27 enrolled · United States
- Sep 9, 2009Phase 1 study in Carcinoma, HepatocellularNCT00976170 · 42 enrolled · United States, Taiwan
- Jan 6, 2012Phase 2 study in Carcinoma, HepatocellularNCT01507168 · 185 enrolled · United States, Belgium, France and more
TargetBeta
“A humanized monoclonal antibody directed against the cell surface oncofetal protein glypican-3 (GPC3) with potential antineoplastic activity. Anti-GPC3 monoclonal antibody GC33 binds to GPC3 and triggers a host immune response against GPC3-expressing tumor cells, which may result in tumor cell de…”NCIt, read by Claude
Other programs on GPC3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033rule | BeOne Medicines | phase 3 | 3 |
| GPC3-targeted Plasmid DNA Vaccine NWRD06rule | Newish Biotech (Wuxi) | phase 2 | 2 |
| Actinium Ac 225 GPC3-targeted Peptide RYZ801 | Bristol-Myers Squibb | phase 2 | 1 |
| Anti-GPC3 T Cell-engaging Antibody AZD9793 | AstraZeneca | phase 2 | 1 |
| Anti-GPC3 Antibody-drug Conjugate ZW251rule | Zymeworks | phase 1 | 1 |
| Anti-GPC3 Antibody-drug Conjugate ABBV-324 | AbbVie | phase 1 | 1 |
| Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926rule | Bayer | phase 1 | 1 |
| ACE723rule | acepodia-biotech-inc | phase 1 | 1 |
| TQB6426rule | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01507168Carcinoma, Hepatocellular · United States, Belgium, France and more | 2 | Completed | Aug 20, 2015 | 185 |
| NCT00976170Carcinoma, Hepatocellular · United States, Taiwan | 1 | Completed | Jul 2013 | 42 |
| NCT00746317Advanced or Metastatic HCC · United States | 1 | Completed | Oct 2010 | 27 |
How it is read
Names in the registry
- “GC33”, 2 entries
- “GC33(RO5137382)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.